Tipiracil
Tipiracil is a thymidine phosphorylase (TPase) inhibitor.
Product Specifications
CAS Number
183204-74-2
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Nucleoside Antimetabolite/Analog; Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Tipiracil.html
Purity
99.98
Solubility
DMSO : < 1 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic)
Smiles
O=C1NC(C(Cl)=C(CN2C(CCC2)=N)N1)=O
Molecular Formula
C9H11ClN4O2
Molecular Weight
242.66
Precautions
H315, H319, H320
References & Citations
[1]Lee SJ, et al. Thymidine phosphorylase influences [ (18) F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41 (7) :1327-35.|[2]Raedler LA. Lonsurf (Trifluridine plus Tipiracil) : A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9 (Spec Feature) :97-100.|[3]Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32 (6) :2319-26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Oncol Rep. 2023 Mar;49 (3) :52.|Biomed Pharmacother. 2021 Jul:139:111672.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mod Rheumatol. 2018 May;28 (3) :495-505.|Patent. US Patent 11110111.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC881920-500 1x 500 µL
CDX2 / Caudal Type Homeobox 2 (GI Epithelial Marker) (PCRP-CDX2-1A3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
